Search results
Results from the WOW.Com Content Network
For premium support please call: 800-290-4726 more ways to reach us
Investing in innovative technology can be an exhilarating journey, providing you with the opportunity to tap into advancements that could shape our future. To navigate this exciting landscape ...
The IGI sustainable agriculture program and its Plant Genomics and Transformation Facility has developed CRISPR protocols for editing over 30 common crop species, [17] and has worked on developing applications including protecting the world's chocolate supply from cacao swollen shoot virus, [55] [56] removing toxic cyanide precursors in cassava ...
In a separate partnership with Broad Institute and Harvard, San Diego-based Illumina will work on research sequencing of single cells and conduct experiments using technology from the company's ...
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland.It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases.
CRISPR-associated transposons have been harnessed for in vitro and in vivo gene editing at different targets, in different hosts, and with different payloads. All CAST components of the Tn6677 system from Vibrio cholerae have been combined into a single plasmid and confirmed to deliver up to 10kb transposons at near 100% efficiency. [ 16 ]
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $50.84, marking a -0.88% move from the previous day.
A gene drive is a natural process [1] and technology of genetic engineering that propagates a particular suite of genes throughout a population [2] by altering the probability that a specific allele will be transmitted to offspring (instead of the Mendelian 50% probability). Gene drives can arise through a variety of mechanisms.